The topic for fiscal year 2021, Cycle 2 is on microbiome/microbiota, SARS-CoV-2/Covid 19 gastrointestinal effects, and SARS-CoV-2 detection in wastewater. Do you have any references for these topics?
Yes, here are a selection of references for all three of the eligible topics:
References for microbiome/microbiota
Berg, Gabriele et al. “Microbiome definition re-visited: old concepts and new challenges.” Microbiome vol. 8,1 103. 30 Jun. 2020, doi:10.1186/s40168-020-00875-0
Kavli Foundation. “About the Microbiome.” The Kavli Foundation, 2020, www.kavlifoundation.org/about-microbiome.
Marchesi, Julian R. “Advancing microbiome research.” Immunology, vol. 154,4 535–536. 25 Jun. 2018, doi:10.1111/imm.12973
Marchesi, Julian R, and Jacques Ravel. “The vocabulary of microbiome research: a proposal.” Microbiome vol. 3 31. 30 Jul. 2015, doi:10.1186/s40168-015-0094-5
Ursell, Luke K et al. “Defining the human microbiome.” Nutrition reviews vol. 70 Suppl 1,Suppl 1 (2012): S38-44. doi:10.1111/j.1753-4887.2012.00493.x
References for SARS-CoV-2/Covid-19 gastrointestinal effects
Bostancıklıoğlu, Mehmet. “Temporal Correlation Between Neurological and Gastrointestinal Symptoms of SARS-CoV-2.” Inflammatory bowel diseases vol. 26,8 (2020): e89-e91. doi:10.1093/ibd/izaa131
Dhar, Jahnvi et al. “Corona Virus Disease-19 pandemic: The gastroenterologists' perspective.” Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 10.1007/s12664-020-01075-2. 12 Aug. 2020, doi:10.1007/s12664-020-01075-2
Lee, Jaewon J et al. “Relative Abundance of SARS-CoV-2 Entry Genes in the Enterocytes of the Lower Gastrointestinal Tract.” Genes vol. 11,6 645. 11 Jun. 2020, doi:10.3390/genes11060645
McIlroy, James R et al. “Intestinal microbiome transfer, a novel therapeutic strategy for COVID-19 induced hyperinflammation?: In reply to, 'COVID-19: Immunology and treatment options', Felsenstein, Herbert McNamara et al. 2020'.” Clinical immunology (Orlando, Fla.) vol. 218 (2020): 108542. doi:10.1016/j.clim.2020.108542
Mönkemüller, Klaus et al. “COVID-19, coronavirus, SARS-CoV-2 and the small bowel.” Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva vol. 112,5 (2020): 383-388.
Scaldaferri, Franco et al. “The Thrilling Journey of SARS-CoV-2 into the Intestine: From Pathogenesis to Future Clinical Implications.” Inflammatory bowel diseases vol. 26,9 (2020): 1306-1314. doi:10.1093/ibd/izaa181
Steele, Scott. “Butts & Guts” podcast. “Gastrointestinal Symptoms and Coronavirus” May 26, 2020. https://my.clevelandclinic.org/podcasts/butts-and-guts/gastrointestional-symptoms-and-coronavirus
White, Tracie. “Gastrointestinal Symptoms Common in COVID-19 Patients, Stanford Medicine Study Reports.” Stanford Medicine News Center, 16 Apr. 2020, med.stanford.edu/news/all-news/2020/04/stomach-complaints-common-in-covid-19-patients.html.
Wastewater detection of SARS-CoV-2
Dennis, Brady. “An early warning system for coronavirus infections could be found in your toilet.” The Washington Post. May 1, 2020. https://www.washingtonpost.com/climate-environment/2020/05/01/coronavirus-sewage-wastewater/
Gable, Lance et al. “Legal and ethical implications of wastewater monitoring of SARS-CoV-2 for COVID-19 surveillance.” Journal of law and the biosciences vol. 7,1 lsaa039. 24 Jun. 2020, doi:10.1093/jlb/lsaa039
Michael-Kordatou, I et al. “Sewage analysis as a tool for the COVID-19 pandemic response and management: the urgent need for optimised protocols for SARS-CoV-2 detection and quantification.” Journal of environmental chemical engineering vol. 8,5 (2020): 104306.
Sen-Crowe, Brendon et al. “Municipal Sewage COVID-19 Testing: A Much Needed Public Health Community Prevention Intervention.” The American surgeon, 3134820951428. 28 Aug. 2020, doi:10.1177/0003134820951428
Venkata Mohan, S et al. “SARS-CoV-2 in Environment Perspective: Occurrence, Persistence, Surveillance, Inactivation and Challenges.” Chemical engineering journal (Lausanne, Switzerland : 1996), 126893. 4 Sep. 2020, doi:10.1016/j.cej.2020.126893
Zaneti, Rafael Newton et al. “Quantitative microbial risk assessment of SARS-CoV-2 for workers in wastewater treatment plants.” The Science of the total environment, vol. 754 142163. 3 Sep. 2020, doi:10.1016/j.scitotenv.2020.142163
What is the definition of “disruptive technology” for the Flash Grants?
Disruptive life sciences technologies are those that may significantly alter the way a market or industry functions, how a product is developed or sold, or how a disease is treated. Disruptive technologies may also displace or render previous products, methods, and business model obsolete.
What is the definition of “translational research phase” of development for the Flash Grants?
The translational research phase of development for life science technologies is the one immediately following the conclusion of the basic research phase (the “how does it work” phase of research) as it enters the earliest stages of product development (the “what is the product/market/route towards commercialization” phase). The translational research phase of development takes laboratory bench-scale research findings and brings them through to the in vivo or clinical trial stage of development.
Can you give some examples of Flash Grant projects?
Examples of Flash Grant projects include:
- Core facility fees or instrumentation usage fees
- Proof-of-concept and feasibility studies for disruptive technologies/discoveries
- Compound screening against a validated target; access to compound libraries
- Prototype development
- Scale-up pilot studies
- Optimization studies
- Algorithm development and validation
- Precision feed ingredient studies
- Plant-based products influenced by environmental growing conditions
- Quality assurance of genetic or biostimulant agricultural measures
Can commercial/business development projects be funded with a Flash grant?
Commercial/business development activities can be conducted as part of a Flash grant, but cannot be the sole activities proposed and undertaken with Flash grant funding. Commercial/business data to be gathered may include voice of customer outreach, IP landscaping, market and competitor data, reimbursement strategies, regulatory approval strategies, etc.
How do you define "precision health"?
Precision health is a multi-disciplinary health care approach that utilizes knowledge about an individual’s genome, environment, lifestyle, and applicable technologic innovation to more precisely and efficiently predict risk, diagnose disease, target therapies, inform health care decisions, and personalize health and wellness plans.
Precision Health combines data about an individual’s genes, environment, and lifestyle with innovation and drivers partnerships to more precisely predict and diagnose disease, target therapies, and personalize health and wellness plans.
How do you define "digital- and data-driven" technologies?
Digital- and data-driven life science technologies are technologies that exist at the convergence of the life sciences with breakthrough electronic data collection/storage/analysis platforms. The Flash Grant may be used to fund the initial development or validation of such a platform that is novel and directly addresses an unmet, life science-related need.
Data-driven life science technologies include but are not limited to:
- FAIR Data Practices
- Metadata capture
- Security, privacy, consenting, and IP protection
- Computational Biology
- Macromolecular structures
- Genome sequences
- Functional genetics
- Macromolecular geometry
- Phylogenetic tree construction
- Protein structure/function
- Gene finding
- Expression data analysis
- Genome-wide association studies
- Transcriptome-wide association studies
- Data Science
- Cloud computing
- Machine learning (ML) and artificial intelligence (AI)
- Lab automation
- FAIR Data Practices